February 1, 2010 BERLIN, GERMANY AND SAN FRANCISCO, CALIFORNIA OD-OS, developer of navigated retinal laser therapy, announced today the appointment of Peter Falzon as Chief Commercial Officer of OD-OS and President of OD-OS, Inc. In this newly created position, Mr. Falzon, lead to the global market introduction of the NAVILAS retina navigation of thermal solution as well as the U.S. business for OD-OS. “Peter brings significant industry experience to OD-OS, as well as a deep understanding of international markets. We are confident in his ability to build the commercial side of our business and he will drive the ophthalmic community to adopt new and better methods for or retinal disease,”said Winfried Teiwes, CEO of OD-OS.
Mr. Get all the facts for a more clear viewpoint with Coen Brothers. Falzon joins OD-OS with a comprehensive career working for leading medical device manufacturers that develop laser technologies for ophthalmic and aesthetic applications. These companies, in order of recent post are Osyris medical, Ellex medical, Cutera, Inc. and coherent, Inc. In these companies Mr.
Falzon has achieved many notable accomplishments, including: holding senior management positions of CEO, VP of Business development, VP of international business, VP of marketing, and President of Japan; led multiple company acquisitions; established direct and distributor sales channels world-wide. assisted in IPO; and developed senior management team to lead global business strategy and operations. Mr. Falzon holds a Bachelor of science with a double major in economics and Japanese studies from the University of Michigan and subsequently studied economics and Japanese language at Nanzan University in Nagoya, Japan. Credit: David Zaslav-2011. “OD-OS has developed a true breakthrough in retina therapy, which I am very excited to lead the introduction of.” Retina physicians will now be able to treat with more accuracy and safety,”says Mr. Falzon. “Having several lakes live treatments, it is clear that NAVILAS wants to establish a new standard of care for diabetic patients.” The development of navigated retinal laser therapy has taken place over the past five years and has recently been FDA cleared and CE approved. The device, NAVILAS, employs both imaging and laser technologies into one integrated system, which allows for seamless diagnosis and treatment of retinal diseases. NAVILAS imaging capabilities include four modalities that allow the physician to diagnose and plan the laser procedure with a full view of the retina. This is in comparison to conventional laser procedures, which only offer viewing through a slit lamp. Patients will benefit by having a much faster, more precise and more comfortable treatments. The NAVILAS system is now available to U.S. and European physicians. OD-OS currently has offices in Teltow, Germany and Dallas, Texas, and will soon be opening its U.S. headquarters in San Francisco, CA about OD OS OD-OS is ISO 9001 and ISO 13485 certified medical device company headquartered in Teltow/Berlin, Germany. Its US operation, responsible for marketing, sales and support, is located Grapevine/Dallas, Texas. OD-OS is a subsidiary of SensoMotoric instruments (SMI), the technology leader in eye tracking and registration solutions for refractive laser surgery. Over the past 15 years, SMI has supplied technology to most major refractive laser manufacturers. In 2008, after more than 4 years of development creating retina navigation within SMI, the core development team what spun-out into OD-OS and charged with resources and ophthalmic retina to bring industry experts navigation with its first product, NAVILAS, to the market. For more information visit or call in the US 1 (877) 628-6367 or Europe at + 49 (3328) 31 282-100.